Related Experiment Video
Updated: Jun 10, 2026
07:32
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
11.4K
Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization
Auni Hamimi Idris1, Che Azurahanim Che Abdullah2,3,4, Nor Azah Yusof4
1Faculty of Chemical and Process Engineering Technology, Universiti Malaysia Pahang, Lebuh Persiaran Tun Khalil Yaakob, Kuantan 26300, Pahang, Malaysia.
Pharmaceutics
|May 27, 2023
Summary
A novel nanostructured lipid carrier loaded with iron oxide nanoparticles and docetaxel (Dtx-MNLC) effectively targets lung cancer cells. This formulation enhances Dtx efficacy while reducing toxicity to healthy lung cells, showing theranostic potential.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Oncology
Background:
- Lung cancer remains a leading cause of cancer mortality, often due to late diagnosis and limited curative options.
- Docetaxel (Dtx) is an effective chemotherapy, but its poor solubility and non-specific toxicity hinder its therapeutic use.
- Theranostic agents offer combined diagnosis and therapy, crucial for improving lung cancer treatment outcomes.
Purpose of the Study:
- To develop a docetaxel-loaded nanostructured lipid carrier with iron oxide nanoparticles (Dtx-MNLC) as a theranostic agent for lung cancer.
- To characterize the physicochemical properties, drug release kinetics, and in vitro cytotoxicity of the developed Dtx-MNLC.
- To evaluate the targeted efficacy and safety profile of Dtx-MNLC compared to commercial docetaxel formulations.
Main Methods:
- Nanostructured lipid carriers (NLCs) were formulated encapsulating iron oxide nanoparticles (IONP) and docetaxel (Dtx).
- Quantification of IONP and Dtx loading was performed using ICP-OES and HPLC.
- Physicochemical characteristics, in vitro drug release, and cytotoxicity assays against A549 (lung cancer) and MRC5 (normal lung) cells were assessed.
Main Results:
- Docetaxel loading percentage was 3.98% w/w, with 0.36 mg/mL IONP incorporated into the Dtx-MNLC.
- The Dtx-MNLC exhibited biphasic drug release, with 40% Dtx released in 6 hours and 80% cumulative release in 48 hours.
- Dtx-MNLC demonstrated enhanced dose-dependent cytotoxicity against A549 cells and reduced toxicity towards MRC5 cells compared to the commercial formulation.
Conclusions:
- Dtx-MNLC effectively inhibits lung cancer cell growth while exhibiting lower toxicity to healthy lung cells.
- The developed Dtx-MNLC formulation shows promise as a theranostic agent for improved lung cancer treatment.
- This nanocarrier system addresses the limitations of docetaxel, enhancing its therapeutic potential in oncology.
